Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
Completed · Phase 2
Conditions studied: Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
In brief
RATIONALE: Amifostine may be effective in reducing pain, numbness, tingling, and other symptoms of peripheral neuropathy. PURPOSE: This phase II trial is studying how well amifostine works in reducing pain, numbness, tingling, and other symptoms of peripheral neuropathy in patients who have received paclitaxel for solid tumors.
Key facts
- Study ID
- NCT00078845
- Run by
- M.D. Anderson Cancer Center
- People needed
- 24
- Starts
- 2004-05-01
- Expected to finish
- 2007-05-01
- Last updated by the study team
- 2012-10-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- CCOP - Central Illinois — Decatur, Illinois, United States
- CCOP - Carle Cancer Center — Urbana, Illinois, United States
- CCOP - Wichita — Wichita, Kansas, United States
- Christus St. Frances Cabrini Center for Cancer Care — Alexandria, Louisiana, United States
- CCOP - Grand Rapids — Grand Rapids, Michigan, United States
- CCOP - Kalamazoo — Kalamazoo, Michigan, United States
- CCOP - Kansas City — Kansas City, Missouri, United States
- Cancer Research for the Ozarks — Springfield, Missouri, United States
- CCOP - Columbus — Columbus, Ohio, United States
- CCOP - Upstate Carolina — Spartanburg, South Carolina, United States
- University of Texas M.D. Anderson CCOP Research Base — Houston, Texas, United States
- CCOP - Scott and White Hospital — Temple, Texas, United States
- CCOP - Northwest — Tacoma, Washington, United States
- CCOP - Marshfield Clinic Research Foundation — Marshfield, Wisconsin, United States
- All Saints Cancer Center at Wheaton Franciscan Healthcare — Racine, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.